NEW YORK, April 10 (Xinhua) — U.S.-China partnership in the biotech sector is promising and will benefit both patients and investors in the two countries, said U.S. biotech firms and investors.

New York, April 09, 2019 (GLOBE NEWSWIRE) — Univest Securities client INmune Bio, Inc. (INmune Bio) (NASDAQ: INMB), a clinical stage immunology biotech company developing therapies in patients’ innate immune system for both cancer and neurological disease, is scheduled to ring The Nasdaq Stock Market Closing Bell at the Nasdaq MarketSite in Times Square at 4:00 PM Eastern time, Tuesday, April 9, 2019. A live webcast of The Nasdaq Stock Market Closing Bell ceremony will be available at: https://new.livestream.com/nasdaq/live.

New York, Feb. 04, 2019 (GLOBE NEWSWIRE) — Univest Securities, LLC, a FINRA and SIPIC member full-service investment bank and securities broker-dealer firm, today announced the closing of the initial public offering (“IPO”) for its client INmune Bio, Inc (“Inmune”), the first biotech IPO in 2019. On best efforts basis, Univest sold, on behalf of Inmune, 1,020,820 shares of its common stock at of $8.00 per share for a total of $8,166,560 in gross proceeds before fees and expenses. Inmune’s common stock is expected to begin trading on The Nasdaq Capital Market (“Nasdaq”) on Monday around 10:30 EST, February 4th, 2019 under the ticker symbol “INMB”.

LA JOLLA, CA, Jan. 15, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (“INmune” or the “Company”), an immunotherapy company focused on developing therapies that harness the patient’s innate immune system to fight disease, today announced the pricing of its initial public offering (“IPO”) at a price to the public of $8.00 per share, for gross proceeds of a minimum of US$8 million and up to US$20 million.